Get the Stockscreener App
0.6102
0.78%
-0.0048
After Hours:
.61
-0.0002
-0.03%
Generation Bio Co stock is traded at $0.6102, with a volume of 514.88K.
It is down -0.78% in the last 24 hours and down -38.36% over the past month.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
See More
Previous Close:
$0.615
Open:
$0.63
24h Volume:
514.88K
Relative Volume:
1.14
Market Cap:
$40.76M
Revenue:
-
Net Income/Loss:
$-126.61M
P/E Ratio:
-0.3113
EPS:
-1.96
Net Cash Flow:
$-60.14M
1W Performance:
-10.26%
1M Performance:
-38.36%
6M Performance:
-76.44%
1Y Performance:
-69.94%
1-Day Range:
$0.5854
$0.6392
1-Week Range:
$0.5854
$0.7516
52-Week Range:
$0.5854
$4.65
Generation Bio Co Stock (GBIO) Company Profile
Name
Generation Bio Co
Sector
Industry
Phone
857-529-5908
Address
301 BINNEY STREET, CAMBRIDGE
Compare GBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GBIO
Generation Bio Co
|
0.6102 | 40.76M | 0 | -126.61M | -60.14M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Generation Bio Co Stock (GBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-19-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Dec-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Feb-18-21 | Initiated | Needham | Buy |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jul-07-20 | Initiated | Jefferies | Buy |
| Jul-07-20 | Initiated | Wedbush | Outperform |
View All
Generation Bio Co Stock (GBIO) Latest News
Generation Bio stock hits 52-week low at $0.6 amid sharp decline - Investing.com
Spore.Bio raises €22 million to deploy a new generation of AI-based microbiology testing - EU-Startups
Layoff Tracker: Kojin Will Soon Close Its Doors, Affecting 25 Employees - BioSpace
Generation Bio stock hits 52-week low at $0.66 By Investing.com - Investing.com Nigeria
Generation Bio stock hits 52-week low at $0.66 - MSN
Insider Buying: Quinn Anthony G., Generation Bio Co [GBIO] Director invested 125,791 shares - Knox Daily
BBAI Stock Sees Surge of Approximately 95.33% in Last Five Days - Knox Daily
Insider Selling: Les Jason, Riot Platforms Inc [RIOT] CHIEF EXECUTIVE OFFICER divested 50,000 shares - Knox Daily
Biotech Executive Powerhouse: Ex-Generation Bio CFO Takes Dual Leadership Role at Rising ADC Developer Tubulis - StockTitan
Pioneering the next generation of bio-based polymers in partnership with London-listed Synthomer - University of York
Ratio Revelations: Generation Bio Co (GBIO)’s Financial Metrics in the Spotlight - The Dwinnex
Generation Bio (GBIO) Stock Price, News & Analysis - MarketBeat
3 US Penny Stocks With Market Cap Under $70M - Yahoo Finance
Generation Bio Co. (NASDAQ:GBIO) Shares Purchased by Barclays PLC - Defense World
Generation Bio chief scientific officer Matthew Stanton to leave role - MSN
Analysts Provide Insight Into Generation Bio Co’s (GBIO) Potential. - Stocks Register
Will Generation Bio (NASDAQ:GBIO) Spend Its Cash Wisely? - Yahoo Finance
Generation Bio Independent Director Acquires 131% More Stock - Yahoo Finance
Generation Bio Co. (NASDAQ:GBIO) Shares Sold by Jane Street Group LLC - Defense World
Generation Bio director Quinn Anthony buys $203k in shares By Investing.com - Investing.com South Africa
Generation Bio Co. (NASDAQ:GBIO) Director Anthony G. Quinn Purchases 125,791 Shares - MarketBeat
Anthony G. Quinn Purchases 85,000 Shares of Generation Bio Co. (NASDAQ:GBIO) Stock - MarketBeat
Generation Bio director Quinn Anthony buys $203k in shares - Investing.com
Seattle immunotherapy startup Umoja Biopharma raises $100M - GeekWire
Needham & Company LLC Issues Pessimistic Forecast for Generation Bio (NASDAQ:GBIO) Stock Price - Defense World
Generation Bio's SWOT analysis: ctLNP tech drives pivot to autoimmune stock - Investing.com Canada
Verdiva Bio, a New Clinical-Stage Cardiometabolic Company, Launches with Over $410M in Series A Financing to Advance Next-Generation Therapies - Business Wire
Finance Watch: Generation Bio, CytomX Right-Size Operations Ahead Of J.P. Morgan - News & Insights
Needham & Company LLC Lowers Generation Bio (NASDAQ:GBIO) Price Target to $8.00 - MarketBeat
Barclays PLC Boosts Position in Generation Bio Co. (NASDAQ:GBIO) - Defense World
Novo Nordisk partners with Variant Bio; Aviceda raises $207M in Series C - Endpoints News
Generation Bio Announces Executive Departures and Appointments - Defense World
Generation Bio Restructures Leadership and Focuses on siRNA - TipRanks
Generation Bio Co. Announces Executive Changes - Marketscreener.com
Generation Bio Co. to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases - Marketscreener.com
Generation Bio Co Stock (GBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):